抗体药物偶联物在晚期三阴性乳腺癌治疗中的研究进展  

Advances of antibody⁃drug conjugates in the treatment of metastatic triple⁃negative breast cancer

作　　者：童一苇[1] 陈小松[1] TONG Yiwei;CHEN Xiaosong(Department of General Surgery,Comprehensive Breast Health Center,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院普外科乳腺疾病诊治中心,上海200025

出　　处：《外科理论与实践》2024年第6期533-536,共4页Journal of Surgery Concepts & Practice

基　　金：上海市科学技术委员会自然科学基金(23ZR1439500)。

摘　　要：三阴性乳腺癌(TNBC)因不表达激素受体和人表皮生长因子受体(HER)-2,故对内分泌治疗和抗HER 2靶向治疗不敏感。抗体药物偶联物(ADC)通过特异性抗体识别癌细胞表面特异性靶抗原,形成抗原-抗体复合物并内化,释放载荷杀伤癌细胞,为晚期TNBC治疗提供新的选择。目前在晚期TNBC中开展研究和临床应用的ADC药物包括:戈沙妥珠单抗、Dato-DXd、SKB264、T-DXd。本文就晚期TNBC中ADC药物的靶点及结构特征作一总结,对相关临床研究中ADC药物的疗效与安全性数据逐一梳理,并对ADC药物在临床应用中尚存的疑问进行探讨。Triple‐negative breast cancer(TNBC)is insensitive to endocrine therapy or anti‐human epidermal growth factor receptor(HER)‐2 targeted therapy due to its lack of expression of hormone receptors and HER‐2.Antibody‐drug conjugates(ADCs)recognize specific antigens on the surface of cancer cells through specific antibodies,form antigen‐antibody complexes that are then internalized,and subsequently release their payloads to kill cancer cells,which offering a novel therapeutic option for metastatic TNBC.Currently,ADCs undergoing research and clinical application in metastatic TNBC include sacituzumab govitecan,datopotamab deruxtecan(Dato‐DXd),SKB264,and trastuzumab deruxtecan(T‐DXd).This article summarized the targets and structural characteristics of ADCs in metastatic TNBC,systematically reviewed the efficacy and safety of ADCs from relevant clinical studies,and discussed the issues of the clinical application of ADCs.

关 键 词：乳腺癌 三阴性 抗体药物偶联物 

分 类 号：R737.9[医药卫生—肿瘤]